Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
Arcturus Therapeutics Holdings Inc. is a Delaware biopharmaceutical company. This Form 8-K reports events beginning December 7, 2021; the report was signed and the related press release was issued on December 13, 2021. The filing does not cover a financial reporting period.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Changes and Corporate Actions
- Board appointment: On December 7, 2021, the Board appointed Dr. Jing L. Marantz as a director, effective immediately, through the next annual meeting or until her successor is elected and qualified.
- Dr. Marantz will receive compensation similar to other non-employee directors, as described in the company’s 2021 annual meeting proxy statement.
- The company disclosed no arrangement or understanding relating to her selection, no family relationship with company directors or executive officers, and no reportable related-party transaction under Item 404(a) of Regulation S-K.
- Code of conduct: The Board adopted a new Code of Business Conduct and Ethics applicable to all directors, officers, employees, and subsidiaries. It replaced the prior code and became effective upon adoption. The company stated that no waiver of the prior code resulted from the adoption.
Management Commentary, Outlook, Risks, and Unusual Items
The filing contains no financial outlook or management guidance. Dr. Marantz’s disclosed background includes senior medical affairs roles at Acceleron Pharma, Alnylam Pharmaceuticals, Alexion Pharmaceuticals, and Biogen. Acceleron was acquired by Merck Sharp & Dohme Corp. in November 2021.
The new Code of Business Conduct and Ethics was filed as Exhibit 14.1. A December 13, 2021 press release announcing Dr. Marantz’s appointment was furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
Investor Verification Items
- Review Dr. Marantz’s director compensation and any future changes to her board role.
- Review the full text of the new Code of Business Conduct and Ethics filed as Exhibit 14.1.
- Confirm the effective date distinction between the earliest reported event, December 7, and the report filing and press release date, December 13, 2021.
- Consult the company’s periodic financial filings for financial performance, liquidity, debt, cash runway, and operating outlook, which are not provided in this Form 8-K.